Augie Diana, PhD

Health Scientist Administrator, Office of Extramural Programs, NIH National Institute of Nursing Research (NINR)

Augie Diana is a Program Director and Team Lead at the National Institute of Nursing Research (NINR).  AT NINR, Dr. Diana oversees the Wellness, and the Technology and Training Team’s grants and activities. He serves as coordinator of NINR’s Small Business Innovation Research (SBIR) and Small Technology Transfer Research (STTR) programs. Dr. Diana previously served as Health Scientist Administrator at the National Institute on Drug Abuse (NIDA) where he oversaw SBIR/STTR grants and contracts and worked to build portfolios of research on physical activity, communications/media, and other areas. Prior to joining NIH, Dr. Diana worked as a Senior Public Health Analyst at the Center for Substance Abuse Prevention (CSAP) where he was responsible for national cross-site evaluations of the State Incentive Grant project, and several data/technology initiatives. Dr. Diana has also worked in Boston and Colorado designing and managing evaluation and research projects at the community and state levels, with a primary focus on substance abuse prevention but also in areas of mental health, crime, delinquency, violence, and youth physical activity.

My Sessions

Lunch – SBIR/STTR Peer Review Mock Study Section

Coronado Room

This session will be led by the NIH Center for Scientific Review, the SBIR/STTR Peer Review Mock Study Section will give you a chance to see a small business peer review study section meeting in action.  You will hear frequent questions asked by reviewers and learn mistakes that small business applicants often make.  This session […]


Planning for Phase III: Networking and Partnering

Miro Room

The SBIR funding mechanism is unique in many ways. But it is the only mechanism that “requires” post-funding actions. Publications, graduate course and thesis completion, and training events or curricula may be expected from other NIH grant mechanisms. Meanwhile, SBIR funds Phases I and II but has built into the funding mechanism a Phase III […]